Nissay Asset Management Corp Japan ADV increased its position in shares of Alkermes Plc (NASDAQ:ALKS) by 4.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,531 shares of the company’s stock after buying an additional 607 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in Alkermes were worth $494,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Alkermes in the fourth quarter valued at $31,645,000. Two Sigma Investments LP lifted its stake in shares of Alkermes by 377.1% in the 4th quarter. Two Sigma Investments LP now owns 479,458 shares of the company’s stock valued at $14,149,000 after purchasing an additional 378,964 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Alkermes by 88.6% in the 4th quarter. Deutsche Bank AG now owns 798,796 shares of the company’s stock valued at $23,570,000 after purchasing an additional 375,322 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Alkermes by 62.4% in the 4th quarter. Canada Pension Plan Investment Board now owns 776,050 shares of the company’s stock valued at $22,899,000 after purchasing an additional 298,289 shares in the last quarter. Finally, First Manhattan Co. lifted its stake in shares of Alkermes by 50.9% in the 4th quarter. First Manhattan Co. now owns 838,894 shares of the company’s stock valued at $24,755,000 after purchasing an additional 282,900 shares in the last quarter. Hedge funds and other institutional investors own 97.45% of the company’s stock.
Shares of Alkermes stock traded down $0.52 on Friday, reaching $21.89. 956,900 shares of the company were exchanged, compared to its average volume of 1,020,240. The firm has a market capitalization of $3.52 billion, a PE ratio of -312.71 and a beta of 1.90. Alkermes Plc has a fifty-two week low of $21.29 and a fifty-two week high of $51.70. The company has a quick ratio of 2.65, a current ratio of 2.94 and a debt-to-equity ratio of 0.25.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, April 25th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.06. Alkermes had a negative return on equity of 2.08% and a negative net margin of 15.86%. The firm had revenue of $223.10 million for the quarter, compared to analyst estimates of $218.84 million. During the same period in the previous year, the firm earned ($0.09) earnings per share. Alkermes’s quarterly revenue was down .9% on a year-over-year basis. Analysts expect that Alkermes Plc will post -0.34 EPS for the current year.
ALKS has been the topic of several research analyst reports. Stifel Nicolaus reduced their price objective on Alkermes from $40.00 to $34.00 and set a “hold” rating on the stock in a research note on Friday, February 15th. Credit Suisse Group raised Alkermes to a “hold” rating and set a $30.00 price target on the stock in a research report on Friday, February 15th. TheStreet raised Alkermes from a “d” rating to a “c-” rating in a research report on Tuesday, February 19th. Zacks Investment Research downgraded Alkermes from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. Finally, ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Six equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $37.83.
In other news, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $36.64, for a total value of $36,640.00. Following the completion of the transaction, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $293,120. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Richard F. Pops sold 60,000 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $25.42, for a total value of $1,525,200.00. Following the sale, the chief executive officer now directly owns 776,433 shares of the company’s stock, valued at $19,736,926.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 196,373 shares of company stock valued at $4,941,720. 4.71% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was reported by Sundance Herald and is the property of of Sundance Herald. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://sundanceherald.com/2019/06/14/nissay-asset-management-corp-japan-adv-increases-holdings-in-alkermes-plc-alks.html.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.